All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Outcomes of coronavirus 2019 disease (COVID-19) in patients with MPN are still not fully understood but the need for evidence-based recommendations on management of antithrombotic and cytoreductive therapies in patients infected with COVID-19 is urgent. In August 2020, a preliminary analysis of the European LeukemiaNet (ELN) observational study of COVD-19 in patients with MPN was presented by the MPN Hub Steering Committee member Tiziano Barbui and his colleagues, at the Texas Virtual MPN Workshop (reviewed on the MPN Hub here), which showed an increased incidence of thromboembolic events and high mortality rates especially in patients with myelofibrosis (MF).1
An approved treatment for MF and polycythemia vera (PV) is the Janus kinase (JAK)1 and JAK2 inhibitor ruxolitinib. The anti-inflammatory and immunomodulatory properties of ruxolitinib have led investigators to assess it as a potential treatment for severe COVID-19; however, results have been disappointing (see article on the MPN Hub here).
The first results of an observational study of the ELN, assessing the impact of ongoing ruxolitinib treatment in patients with MPN who develop COVID-19, was recently published by Tiziano Barbui and co-authors in Leukemia, which we have summarized below.
This multicenter, observational, retrospective study analysed 180 adults with MPN treated in 38 centers across Europe (Italy, Spain, UK, France, Poland, and Germany).
Data were collected between February 15 and May 31, 2020, and included demographics, comorbidities, medications, laboratory tests, imaging, and treatments and supportive interventions for COVID-19. The median follow-up was 50 days. Additionally, information was collected on MPN driver mutations, duration of MPN prior to COVID-19 infection, presence of splenomegaly, and use of cytoreductive drugs.
Table 1. Multivariable analysis of risk factors for mortality in patients with COVID-191
OR, odds ratio; CI, confidence interval; MF, myelofibrosis; ICU, intensive care unit. |
||
Factor |
OR (95% CI) |
p value |
---|---|---|
Age |
1.07 (1.02–1.11) |
0.003 |
Male sex |
2.48 (1.01–6.07) |
0.047 |
Diagnosis of MF |
1.69 (0.61–4.66) |
0.315 |
Chronic heart disease |
2.18 (0.64–7.36) |
0.210 |
Respiratory support |
10.0 (2.94–34.0) |
< 0.001 |
ICU admission |
4.93 (1.36–17.9) |
0.015 |
Ruxolitinib administration |
2.40 (0.72–8.02) |
0.154 |
Ruxolitinib discontinuation |
8.51 (1.14–63.4) |
0.037 |
Mortality in patients with MF after a COVID-19 diagnosis was higher than in patients with ET, PV, or pre-PMF. None of the MPN-directed therapies were associated with a higher risk of death when used in patient diagnosed with COVID-19.
However, rapid ruxolitinib discontinuation after COVID diagnosis was associated with a significantly higher mortality risk, as shown by multivariable analysis. A possible explanation could be the induction of proinflammatory cytokine release after ruxolitinib discontinuation which may aggravate COVID-19.
The authors acknowledge that their subgroup of 11 patients who discontinued ruxolitinib treatment is small, but the analysis was adjusted for multiple confounders and remained robust after a sensitivity analysis. They suggest that their observation should be spread among patient and clinician communities while a larger observational study with longer follow-up can confirm the results.
Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35(2):485-493. DOI: 10.1038/s41375-020-01107-y
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox